Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q1 EPS of ($0.05), $0.07 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $37.1 million versus the consensus estimate of $47.17 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2023 revenue of $205-220 million, versus the consensus of $228.2 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.